Users of the new Galaxy Watch 3 will now be able to monitor their heartbeat.
Samsung announced that the electrocardiogram (ECG) monitoring app had been awarded all clarity by the US Food and Drug Administration (FDA).
Until now, South Korea was the only country where Samsung’s ECG monitoring function was approved.
Available via the Samsung Health Monitor app when connected to compatible Galaxy smartphones, the ECG screen can be used to monitor the user’s heart rhythm and look for signs of irregularities or atrial fibrillation (AFIB).
Samsung launched the ECG function on the new Galaxy Watch 3 and Watch Active 2 in the US for the first time.
In 2017, Samsung, along with Apple, Fitbit, and other companies, joined a pilot program led by the Food and Drug Administration to accelerate the approval of healthcare-related apps and services.
Scott Gottlieb, FDA Commissioner, said, “We need to update our regulatory framework so that it matches the type of innovation we are being asked to evaluate, and helps promote useful technology.” is.”
“These pilot participants will help shape a better, more flexible approach to digital health technology that focuses on one developer rather than one individual product.”
The launch of the Galaxy Watch 3 with ECG display comes a week after rival Apple announced the launch of the Apple Watch Series 6 with a blood oxygen sensor.